Fatal and Non-fatal Health Incidents Related to Recreational Ecstasy Use

Overview

Journal J Psychopharmacol

Publisher Sage Publications

Specialty Pharmacology

Date 2020 Jan 8

PMID 31909673

Citations 6

Authors

Jan van Amsterdam

Ed Pennings

Wim van den Brink

Affiliations

Soon will be listed here.

Abstract

Background: The recreational drug ecstasy (3,4-methylenedioxymethamphetamine) is currently used world-wide. Severe (including fatal) health incidents related to ecstasy have been reported but a risk assessment of acute non-fatal and fatal ecstasy-related health incidents has never been performed.

Methods: In the current risk assessment review, national data of non-fatal health incidents collected in the Netherlands were combined with the nationwide exposure to ecstasy, that is, last-year prevalence of ecstasy use. In addition, the annual number of ecstasy-related deaths in Great Britain (Scotland, Wales and England) was used to assess the risk of fatal ecstasy-related cases.

Results: In the Netherlands, the estimated risk of a moderate to severe acute health incident following the use of ecstasy is one in 900 pills (0.11%), whereas for cocaine it is one in 1600 doses (0.06%) and for gamma-hydroxybutyrate one in 95 doses (1.05%). With respect to ecstasy-related deaths in Great Britain, the estimated risk of ecstasy alone per user is 0.01-0.06%, which is close to the range of the fatality risk in chronic alcohol users (0.01-0.02%), amphetamine users (0.005%) and cocaine users (0.05%), but much lower than that of opiate use (heroin and morphine: 0.35%).

Conclusion: The current review shows that almost no data are available on the health risks of ecstasy use. The few data that are available show that ecstasy is not a safe substance. However, compared to opiates (heroin, morphine), the risk of acute ecstasy-related adverse health incidents per ecstasy user and per ecstasy use session is relatively low.

Citing Articles

Hofmann vs. Paracelsus: Do Psychedelics Defy the Basics of Toxicology?-A Systematic Review of the Main Ergolamines, Simple Tryptamines, and Phenylethylamines.

Henriquez-Hernandez L, Rojas-Hernandez J, Quintana-Hernandez D, Borkel L Toxics. 2023; 11(2).

PMID: 36851023 PMC: 9963058. DOI: 10.3390/toxics11020148.

3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs.

Lopez-Arnau R, Camarasa J, Carbo M, Nadal-Gratacos N, Puigseslloses P, Espinosa-Velasco M Front Psychiatry. 2022; 13:990405.

PMID: 36262632 PMC: 9574023. DOI: 10.3389/fpsyt.2022.990405.

MDMA for the Treatment of Negative Symptoms in Schizophrenia.

Arnovitz M, Spitzberg A, Davani A, Vadhan N, Holland J, Kane J J Clin Med. 2022; 11(12).

PMID: 35743326 PMC: 9225098. DOI: 10.3390/jcm11123255.

Hard Boiled: Alcohol Use as a Risk Factor for MDMA-Induced Hyperthermia: a Systematic Review.

van Amsterdam J, Brunt T, Pierce M, van den Brink W Neurotox Res. 2021; 39(6):2120-2133.

PMID: 34554408 PMC: 8639540. DOI: 10.1007/s12640-021-00416-z.

Amphetamine-Decreased Progesterone and Estradiol Release in Rat Granulosa Cells: The Regulatory Role of cAMP- and Ca-Mediated Signaling Pathways.

Chen C, Chen C, Chen C, Wang P, Mundel T, Liao Y Biomedicines. 2021; 9(5).

PMID: 33947083 PMC: 8145484. DOI: 10.3390/biomedicines9050493.

References

Liu R . Hypothermic effects of marihuana, marihuana derivatives and chlorpromazine in laboratory mice. Res Commun Chem Pathol Pharmacol. 1974; 9(2):215-28. View

Parrott A . MDMA is certainly damaging after 25 years of empirical research: a reply and refutation of Doblin et al. (2014). Hum Psychopharmacol. 2014; 29(2):109-19. DOI: 10.1002/hup.2390. View

Horyniak D, Degenhardt L, Smit D, Munir V, Johnston J, Fry C . Pattern and characteristics of ecstasy and related drug (ERD) presentations at two hospital emergency departments, Melbourne, Australia, 2008-2010. Emerg Med J. 2013; 31(4):317-22. DOI: 10.1136/emermed-2012-202174. View

Szigeti B, Winstock A, Erritzoe D, Maier L . Are ecstasy induced serotonergic alterations overestimated for the majority of users?. J Psychopharmacol. 2018; 32(7):741-748. DOI: 10.1177/0269881118767646. View

HALL A . "Ecstasy" and the anaesthetist. Br J Anaesth. 1998; 79(6):697-8. DOI: 10.1093/bja/79.6.697. View

Brunt T, Koeter M, Niesink R, van den Brink W . Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users. Psychopharmacology (Berl). 2011; 220(4):751-62. DOI: 10.1007/s00213-011-2529-4. View

Nutt D, King L, Saulsbury W, Blakemore C . Development of a rational scale to assess the harm of drugs of potential misuse. Lancet. 2007; 369(9566):1047-53. DOI: 10.1016/S0140-6736(07)60464-4. View

Parrott A, Milani R, Gouzoulis-Mayfrank E, Daumann J . Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users. J Neural Transm (Vienna). 2007; 114(8):959-68. DOI: 10.1007/s00702-007-0715-7. View

van Amsterdam J, Opperhuizen A, Koeter M, van den Brink W . Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population. Eur Addict Res. 2010; 16(4):202-7. DOI: 10.1159/000317249. View

10.

Mohamed W, Ben Hamida S, Cassel J, Pereira de Vasconcelos A, Jones B . MDMA: interactions with other psychoactive drugs. Pharmacol Biochem Behav. 2011; 99(4):759-74. DOI: 10.1016/j.pbb.2011.06.032. View

11.

Parrott A, Downey L, Roberts C, Montgomery C, Bruno R, Fox H . Recreational 3,4-methylenedioxymethamphetamine or 'ecstasy': Current perspective and future research prospects. J Psychopharmacol. 2017; 31(8):959-966. DOI: 10.1177/0269881117711922. View

12.

Gowing L, Henry-Edwards S, Irvine R, Ali R . The health effects of ecstasy: a literature review. Drug Alcohol Rev. 2002; 21(1):53-63. DOI: 10.1080/09595230220119363. View

13.

Parrott A . Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research. Hum Psychopharmacol. 2013; 28(4):289-307. DOI: 10.1002/hup.2318. View

14.

Rosenson J, Smollin C, Sporer K, Blanc P, Olson K . Patterns of ecstasy-associated hyponatremia in California. Ann Emerg Med. 2006; 49(2):164-71, 171.e1. DOI: 10.1016/j.annemergmed.2006.09.018. View

15.

King L, Corkery J . An index of fatal toxicity for new psychoactive substances. J Psychopharmacol. 2018; 32(7):793-801. DOI: 10.1177/0269881118754709. View

16.

Scholey A, Parrott A, Buchanan T, Heffernan T, Ling J, Rodgers J . Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study. Addict Behav. 2004; 29(4):743-52. DOI: 10.1016/j.addbeh.2004.02.022. View

17.

Steele T, Katz J, Ricaurte G . Evaluation of the neurotoxicity of N-methyl-1-(4-methoxyphenyl)-2-aminopropane (para-methoxymethamphetamine, PMMA). Brain Res. 1992; 589(2):349-52. DOI: 10.1016/0006-8993(92)91298-s. View

18.

Benzenhofer U, Passie T . Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin. Addiction. 2010; 105(8):1355-61. DOI: 10.1111/j.1360-0443.2010.02948.x. View

19.

King L, Corkery J . An index of fatal toxicity for drugs of misuse. Hum Psychopharmacol. 2010; 25(2):162-6. DOI: 10.1002/hup.1090. View

20.

van Amsterdam J, Nutt D, Phillips L, van den Brink W . European rating of drug harms. J Psychopharmacol. 2015; 29(6):655-60. DOI: 10.1177/0269881115581980. View